feedback

Course Director

Naiyer Rizvi, MD
Naiyer Rizvi, MD

Columbia University Medical Center
New York, New York

Faculty

Omid Hamid
Omid Hamid, MD

The Angeles Clinic and Research Institute
Cedars Sinai Medical Care Foundation
Los Angeles, California

Solange Peters
Solange Peters, MD, PhD

Lausanne University Hospital
Lausanne, Switzerland

Thomas Powles
Thomas Powles, MRCP, MBBS, MD

Barts Cancer Centre
Barts Cancer Institute, Centre for Experimental Cancer Medicine
London, England

Nadeem Riaz
Nadeem Riaz, MD, MSc

Memorial Sloan Kettering Cancer Center
New York, New York

Accredited by

0 default

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2018-Jun-18
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, experts discuss the latest and greatest advances in immuno-oncology. They explore what's new on the biomarker development front to help determine which patients are most likely to benefit from different immune-based treatment approaches, which new agents and rational combinations are showing the most promise, and what all of this means for research and clinical practice now and moving forward.

Upon completion of this activity, participants should be better able to:
  • Analyze the role, benefits, and limitations of current biomarkers (PD-L1 expression, MMR/MSI status) as predictors of benefit from cancer immunotherapies
  • Evaluate the latest data on the utility of different biomarkers in guiding patient selection and predicting benefit from agents directed to various immune targets (PD-1/PD-L1, CTLA-4, LAG-3, IDO, etc.) and combinations based on these agents in different cancers
  • Describe the rationale for and evidence supporting the use of TMB as an immunotherapy biomarker
  • Discuss the benefits and limitations of different methodologies and platforms, including NGS, in assessing TMB and other immunotherapy biomarkers
  • Characterize the potential role of other novel strategies and technologies in cancer immunotherapy biomarker development
  • Implement best practices for cancer immunotherapy biomarker testing and interpretation in clinical and laboratory settings
  • Select patients with cancer (eg, lung cancer, melanoma, GI and GU cancers, and others) who are most likely to benefit from the latest cancer immunotherapies and combinatorial approaches, either in the context of clinical practice or clinical trials, based on all the relevant factors necessary for personalized treatment decisions, including latest efficacy and safety data and appropriate, evidence-based immunotherapy biomarker assessments

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, clinical and biomedical researchers, and other professionals interested in cancer immunotherapies and combinations, immunotherapy biomarkers, and precision immuno-oncology.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 18, 2018 - June 17, 2019
Time to Complete: 120 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Naiyer Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, New York

Naiyer Rizvi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Merck KGaA; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Shareholder in Gritstone Oncology where Dr. Rizvi is a Co-Founder.
Advisory Board for NeoGenomics Laboratories, Inc.
Other Financial or Material Support from Patent pending; Filed by MSKCC, determinants of cancer response to immunotherapy by PD-1 blockade (PCT/US2015/062208). Board of Directors for and Shareholder in ARMO BioSciences.
Naiyer Rizvi, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and biomarker testing platforms.

Faculty

Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director of Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, California

Omid Hamid, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Speakers Bureau participant with Amgen; Bristol-Myers Squibb; Genentech, Inc.; and Novartis Pharmaceuticals Corporation.
Advisory Board for Amgen; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Omid Hamid, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and biomarker testing platforms.

Solange Peters, MD, PhD
Lausanne University Hospital
ETOP Scientific Coordinator
JTO/IASLC Deputy Editor
ESMO President Elect
Lausanne, Switzerland

Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Boehringer Ingelheim International GmbH; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd; MSD (Merck Sharp and Dohme); Merck Serono; Novartis AG; Pfizer Inc.; and Takeda Pharmaceutical Company Limited.
Advisory Board for Boehringer Ingelheim International GmbH; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd; MSD (Merck Sharp and Dohme); Merck Serono; Novartis AG; Pfizer Inc.; and Takeda Pharmaceutical Company Limited.
Prof. Solange Peters, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and biomarker testing platforms.

Thomas Powles, MRCP, MBBS, MD
Professor of Urology Cancer
Director of Barts Cancer Centre
Barts Cancer Institute, Centre for Experimental Cancer Medicine
London, England

Thomas Powles, MRCP, MBBS, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca and F. Hoffmann-La Roche Ltd.
Speakers Bureau participant with AstraZeneca; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Advisory Board for AstraZeneca; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Prof. Thomas Powles, MRCP, MBBS, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and biomarker testing platforms.

Nadeem Riaz, MD, MSc
Radiation Oncologist
Associate Director of Genomics Operations
Immunogenomics and Precision Oncology Platform
Memorial Sloan Kettering Cancer Center
New York, New York

Nadeem Riaz, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb and Pfizer, Inc.
Nadeem Riaz, MD, MSc, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and immunotherapy biomarker testing platforms.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through educational grants from Bristol-Myers Squibb, Foundation Medicine, Inc., Incyte Corporation, and Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.